deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01085214

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma

A Phase 2 Study of AZD6244 in Multiple Myeloma

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Plasma Cell Myeloma Refractory Plasma Cell Myeloma
Interventions Laboratory Biomarker Analysis Selumetinib
Updated 6 times since 2017 Last updated: Jul 24, 2015 Started: Mar 31, 2010 Primary completion: Mar 31, 2012 Completion: Mar 31, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma and is currently completed. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations